Oh Jaewon, Kim Wonho, Kim Gee-Hee, Kim Hack-Lyoung, Park Sang-Don, Min Kyung Wan, Hyun Dongkeun, Hong Jun Hwa, Lim Soo, Bae Ji-Hwan, Shin Jinho
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Division of Cardiology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Republic of Korea.
J Hum Hypertens. 2025 Jul 14. doi: 10.1038/s41371-025-01043-3.
This pioneering study investigated the real-life effectiveness of single-pill combination (SPC) antihypertensive therapy in patients with uncontrolled blood pressure (BP) and cardiovascular risk factors. After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension.
这项开创性研究调查了单片复方制剂（SPC）抗高血压疗法在血压控制不佳且伴有心血管危险因素患者中的实际疗效。在用奥美沙坦酯/苯磺酸氨氯地平/氢氯噻嗪治疗24周后，患有明显顽固性高血压的成年人收缩压显著降低，约80%的患者达到了目标血压。SPC疗法可能会提高假性顽固性高血压患者的依从性，是治疗顽固性高血压的一种潜在有效疗法。
